Dihydromyricetin reverses cognitive dysfunction in type 2 diabetic rats via inhibition of the JNK-ERS axis

doi:10.5246/jcps.2025.11.075

Abstract

Abstract:

Recent studies have demonstrated that dihydromyricetin (DHM) exerts a protective effect against central nervous system injury. Building on these findings, the present study aimed to investigate whether DHM could ameliorate cognitive deficits in a type 2 diabetes mellitus (T2DM) rat model, and to explore whether this effect involved inhibition of the JNK signaling pathway and suppression of endoplasmic reticulum stress (ERS). To establish the T2DM model, Sprague Dawley (SD) rats were fed a high-fat, high-sugar diet in combination with a single intraperitoneal injection of streptozotocin (STZ). Fasting blood glucose levels were measured from tail vein samples, and cognitive performance was evaluated using the Morris water maze (MWM) and Y-maze tests. Following behavioral assessments, the animals were sacrificed by cervical dislocation, and hippocampal tissues were collected for further analysis. Histological examination using hematoxylin-eosin (H&E) staining was performed to assess hippocampal neuronal damage. Western blotting (WB) analysis was employed to quantify the expression of pro-apoptotic protein Bax and anti-apoptotic protein Bcl-2, while ELISA was conducted to measure levels of phosphorylated tau (p-tau) and amyloid-β (Aβ) in the hippocampus. After 12 weeks of oral administration of DHM (250 mg/kg/d), relevant biomarkers were re-evaluated to determine the compound's impact on cognitive function and hippocampal integrity. Additionally, rats from each group received intracerebroventricular injections of various pharmacological agents, namely, TUDCA (an ERS inhibitor), STZ, SP600125 (a JNK inhibitor), and anisomycin (AMY, a JNK activator). WB analysis was further conducted to assess the expression of JNK, phosphorylated JNK (p-JNK), and ERS-associated proteins Bip and p-PERK in hippocampal tissue. The results confirmed that combining a high-fat, high-sugar diet with low-dose STZ injection for 4 weeks effectively established a T2DM model. Compared with the control group, T2DM rats exhibited significant cognitive deficits, increased neuronal apoptosis in the hippocampus, and elevated hippocampal levels of p-tau and Aβ. Notably, DHM treatment markedly reversed these pathological changes in T2DM rats, whereas it had no significant effects on control animals. Moreover, administration of TUDCA and SP600125 similarly mitigated cognitive impairment, neuronal apoptosis, and the accumulation of p-tau and Aβ in diabetic rats. Conversely, activation of ERS and JNK signaling using tunicamycin (TUN) and AMY, respectively, resulted in exacerbated cognitive decline, increased neuronal apoptosis, and higher levels of p-tau and Aβ. In conclusion, these findings suggested that DHM effectively alleviated cognitive dysfunction in T2DM rats, potentially through the inhibition of JNK signaling and subsequent attenuation of ERS, thereby reducing neuronal apoptosis and the pathological accumulation of p-tau and Aβ in the hippocampus.

Key words: Dihydromyricetin, Type 2 diabetes, Cognitive dysfunction, JNK signaling, Endoplasmic reticulum stress

Supporting:

Huijie Lv, Jun Peng, Xu Huang, Tuo Xu, Tianchen Zhang, Hongyan Ling. Dihydromyricetin reverses cognitive dysfunction in type 2 diabetic rats via inhibition of the JNK-ERS axis[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(11): 1003-1023.

Figures/Tables 10

References 54

[1]	Majety, P.; Lozada Orquera, F.A.; Edem, D.; Hamdy, O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Endocrinol. Lausanne. 2023, 14, 1118848.
[2]	Gunawardena, H.; Silva, R.; Sivakanesan, R. Insulin resistance and dyslipidemia predicts the antioxidant status of individuals with type 2 diabetes mellitus. IDF World Diabetes Congress. 2019.
[3]	Hanson, A.J.; Rubinow, K.B. Optimizing clinical phenotyping to better delineate the complex relationship between type 2 diabetes and Alzheimer’s disease. Clin. Transl. Sci. 2021, 14, 1681–1688.
[4]	Wu, W.J.; Qiu, J.; Wang, A.L.; Li, Z.G. Impact of whole cereals and processing on type 2 diabetes mellitus: a review. Crit. Rev. Food Sci. Nutr. 2020, 60, 1447–1474.
[5]	Sun, Y.; Liu, S.S.; Yang, S.W.; Chen, C.; Yang, Y.T.; Lin, M.Y.; Liu, C.; Wang, W.M.; Zhou, X.D.; Ai, Q.D.; Wang, W.; Chen, N.H. Mechanism of dihydromyricetin on inflammatory diseases. Front. Pharmacol. 2022, 12, 794563.
[6]	Xie, J.B.; Zhang, T.T.; Li, P.C.; Wang, D.; Liu, T.; Xu, S.L. Dihydromyricetin attenuates cerebral ischemia reperfusion injury by inhibiting SPHK1/mTOR signaling and targeting ferroptosis. Drug Des. Devel. Ther. 2022, 16, 3071–3085.
[7]	Ding, H.R.; Cheng, Q.C.; Fang, X.; Wang, Z.Y.; Fang, J.Y.; Liu, H.C.; Zhang, J.W.; Chen, C.H.; Zhang, W.G. Dihydromyricetin alleviates ischemic brain injury by antagonizing pyroptosis in rats. Neurotherapeutics. 2023, 20, 1847–1858.
[8]	Wei, Y.C.; Hu, Y.H.; Qi, K.M.; Li, Y.; Chen, J.X.; Wang, R.G. Dihydromyricetin improves LPS-induced sickness and depressive-like behaviors in mice by inhibiting the TLR4/Akt/HIF1a/NLRP3 pathway. Behav. Brain Res. 2022, 423, 113775.
[9]	Guo, C.H.; Cao, T.; Zheng, L.T.; Waddington, J.L.; Zhen, X.C. Development and characterization of an inducible dicer conditional knockout mouse model of Parkinson’s disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin. Acta Pharmacol. Sin. 2020, 41, 499–507.
[10]	Ren, Z.X.; Zhao, Y.F.; Cao,T. Dihydromyricetin protects neurons in MPTP-induced Parkinson disease via suppressing activity of glycogen synthase kinase-3 beta. Chin. J. Pharm. Toxicol. 2016, 30, 441–441.
[11]	Liu, M.M.; Guo, H.; Li, Z.Y.; Zhang, C.H.; Zhang, X.P.; Cui, Q.H.; Tian, J.Z. Molecular level insight into the benefit of myricetin and dihydromyricetin uptake in patients with Alzheimer’s diseases. Aging Neurosci. 2020, 12, 601603.
[12]	Lv, H.J.; Zhu, Z.M.; Chen, W.Z. Dihydromyricetin inhibits high glucose induced PC12 cells apoptosis by down-regulating JNK Pathway. Prog. Biochem. Biophys. 2018, 45, 663–671.
[13]	Kao, S.J.; Lee, W.J.; Chang, J.H.; Chow, J.M.; Chung, C.L.; Hung, W.Y.; Chien, M.H. Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer. Environ Toxicol. 2017, 32, 1426–1438.
[14]	Huang, Y.; You, S.M.; S hen, Y.B. Dihydromyricetin enhances the sensitivity of drug-resistant malignant melanoma cells to carboplatin via the SIRT1/JNK pathway. Chin. J. Modern Appl. Pharm. 2017, 34, 1689–1694.
[15]	Park, E.; Chun, H.S. Protective effects of quercetin on dieldrin-induced endoplasmic reticulum stress and apoptosis in dopaminergic neuronal cells. Neuroreport. 2016, 27, 1140–1146.
[16]	Tsai, J.J.; Kuo, H.C.; Lee, K.F.; Tsai, T.H. Glycyrrhizin represses total parenteral nutrition-associated acute liver injury in rats by suppressing endoplasmic reticulum stress. Int. J. Mol. Sci. 2013, 14, 12563–12580.
[17]	Takano, K.; Tabata, Y.; Kitao, Y.; Murakami, R.; Suzuki, H.; Yamada, M.; Iinuma, M.; Yoneda, Y.; Ogawa, S.; Hori, O. Methoxyflavones protect cells against endoplasmic reticulum stress and neurotoxin. Am. J. Physiol. Cell Physiol. 2007, 292, C353–C361.
[18]	Kwon, K.; Kwon, Y.S.; Kim, S.W.; Yu, K.; Lee, K.H.; Kwon, O.Y. Luteolin-induced apoptosis through activation of endoplasmic reticulum stress sensors in pheochromocytoma cells. Mol. Med. Rep. 2017, 16, 380–386.
[19]	Liu, H.; Hurile, B.; Xiong, Y.; Wei, C.X.; Xuan, L.Y.; Wang, Y.; Zhao, M. Effects of total flavonids of astragalus on arrhythmia, endoplasmic reticulum stress in mice with viral myocarditis. Chin. J. Appl. Physiol. 2018, 34, 16–18.
[20]	Quiñones, M.; Al-Massadi, O.; Folgueira, C.; Bremser, S.; Gallego, R.; Torres-Leal, L.; Haddad-Tóvolli, R.; García-Caceres, C.; Hernandez-Bautista, R.; Lam, B.Y.H.; Beiroa, D.; Sanchez-Rebordelo, E.; Senra, A.; Malagon, J.A.; Valerio, P.; Fondevila, M.F.; Fernø, J.; Malagon, M.M.; Contreras, R.; Pfluger, P.; Brüning, J.C.; Yeo, G.; Tschöp, M.; Diéguez, C.; López, M.; Claret, M.; Kloppenburg, P.; Sabio, G.; Nogueiras, R. p53 in AgRP neurons is required for protection against diet-induced obesity via JNK1. Nat. Commun. 2018, 9, 3432.
[21]	Chung, Y.; Lee, H. Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization. Sci. Rep. 2021, 11, 15265.
[22]	Cukierman, T.; Gerstein, H.C.; Williamson, J.D. Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia. 2005, 48, 2460–2469.
[23]	Cheng, G.; Huang, C.; Deng, H.; Wang, H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 2012, 42, 484–491.
[24]	Liu, Z.C.; Fu, Z.Q.; Song, J.; Zhang, J.Y.; Wei, Y.P.; Chu, J.; Han, L.; Qu, N.; Wang, J.Z.; Tian, Q. Bip enhanced the association of GSK-3β with tau during ER stress both in vivo and in vitro. J. Alzheimers Dis. 2012, 29, 727–740.
[25]	Resende, R.; Ferreiro, E.; Pereira, C.; Oliveira, C.R. ER stress is involved in Aβ-induced GSK-3β activation and tau phosphorylation. J. Neurosci. Res. 2008, 86, 2091–2099.
[26]	Buccarello, L.; Sclip, A.; Sacchi, M.; Castaldo, A.M.; Bertani, I.; ReCecconi, A.; Maestroni, S.; Zerbini, G.; Nucci, P.; Borsello, T. The c-Jun N-terminal kinase plays a key role in ocular degenerative changes in a mouse model of Alzheimer disease suggesting a correlation between ocular and brain pathologies. Oncotarget. 2017, 8, 83038–83051.
[27]	Bitel, C.L.; Kasinathan, C.; Kaswala, R.H.; Klein, W.L.; Frederikse, P.H. Amyloid-β and tau pathology of Alzheimer’s disease induced by diabetes in a rabbit animal model. J. Alzheimers Dis. 2012, 32, 291–305.
[28]	Kim, B.; Backus, C.; Oh, S.; Feldman, E.L. Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer’s disease. J. Alzheimers Dis. 2013, 34, 727–739.
[29]	Jakobsen, J.; Sidenius, P.; Gundersen, H.J.G.; Østerby, R. Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes. 1987, 36, 597–601.
[30]	Garris, D.R.; Diani, A.R.; Smith, C.; Gerritsen, G.C. Depopulation of the ventromedial hypothalamic nucleus in the diabetic Chinese hamster. Acta Neuropathol. 1982, 56, 63–66.
[31]	Liang, J.Y.; Guo, F.; Cao, S.F.; Zhao, K.; Zhao, K.X.; Wang, H.F.; Shao, X.F.; Wei, Y.Y.; Zhang, C.D.; Zheng, Y.H.; Xu, F. γ-Aminobutyric acid (GABA) alleviated oxidative damage and programmed cell death in fresh-cut pumpkins. Plant Physiol. Biochem. 2022, 180, 9–16.
[32]	Anarkooli, I.J.; Ganji, H.B.; Pourheidar, M. The protective effects of insulin and natural honey against hippocampal cell death in streptozotocin-induced diabetic rats. J. Diabetes Res. 2014, 2014, 491571.
[33]	Xu, H.; Li, H.; Liu, D.X.; Wen, W.; Xu, M.; Frank, J.A.; Chen, J.; Zhu, H.N.; Grahame, N.J.; Luo, J. Chronic voluntary alcohol drinking causes anxiety-like behavior, thiamine deficiency, and brain damage of female crossed high alcohol preferring mice. Pharmacol. 2021, 12, 614396.
[34]	Mao, X.; Meng, J.; Mao, J. Zhang, H.L. Effects of acupuncture on endoplasmic reticulum stress and apoptosis in CA1 region of hippocampus of rats with Alzheimer’s disease. J. Hainan Med. Coll. 2019, 25, 1209–1214.
[35]	Montibeller, L.; de Belleroche, J. Amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) are characterised by differential activation of ER stress pathways: focus on UPR target genes. Cell Stress. Chaperones. 2018, 23, 897–912.
[36]	Stutzbach, L.; Hawk, M.; Gilman, S.; Lee, V.; Trojanowski, J.; Schellenberg, G. ER stress in Alzheimer’s disease and PSP: common disease mechanism? Alzheimers. Dement. 2012, 8, 460–461.
[37]	Zhu, W.; Zhao, L.; Li, T.; Xu, H.; Ding, Y.X.; Cui, G.Q. Docosahexaenoic acid ameliorates traumatic brain injury involving JNK-mediated Tau phosphorylation signaling. Neurosci. Res. 2020, 157, 44–50.
[38]	Zhang, H.; Zhang, L.; Zhou, D.M.; Li, H.F.; Xu, Y. ErbB4 mediates amyloid β-induced neurotoxicity through JNK/tau pathway activation: Implications for Alzheimer’s disease. J. Comp. Neurol. 2021, 529, 3497–3512.
[39]	Orejana, L.; Barros-Miñones, L.; Aguirre, N.; Puerta, E. Implication of JNK pathway on tau pathology and cognitive decline in a senescence-accelerated mouse model. Exp. Gerontol. 2013, 48, 565–571.
[40]	Sun, X.Y.; Dong, Q.X.; Zhu, J.; Sun, X.; Zhang, L.F.; Qiu, M.; Yu, X.L.; Liu, R.T. Resveratrol rescues tau-induced cognitive deficits and neuropathology in a mouse model of tauopathy. Curr. Alzheimer Res. 2019, 16, 710–722.
[41]	Wu, T.T.; Chai, L.M.; Yang,Y.X. Action mechanism of Bushen Yifei Xiaozheng Recipe on regulation of endoplasmic reticulum stress by intervening expression of key molecules of JNK apoptosis signaling pathway in pulmonary fibrosis rats. J. Mod. Integr. Med. 2016, 25, 2053–2056.
[42]	Wu, Y.; Yuan, Y.; Wu, C.B.; Jiang, T.; Wang, B.N.; Xiong, J.; Zheng, P.P.; Li, Y.Y.; Xu, J.Y.; Xu, K.; Liu, Y.Q.; Li, X.K.; Xiao, J. Corrigendum: the reciprocal causation of the ASK1-JNK1/2 pathway and endoplasmic reticulum stress in diabetes-induced cognitive decline. Front. Cell Dev. Biol. 2021, 9, 639486.
[43]	Luchsinger, J.A. Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J. Alzheimers Dis. 2010, 20, 723–736.
[44]	Ryan, C.M.; Freed, M.I.; Rood, J.A.; Cobitz, A.R.; Waterhouse, B.R.; Strachan, M.W. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006, 29, 345–351.
[45]	Lin, B.; Zhang, Z.L.; Yu, L.Y.; Guo, L.H. CMV-hFasL transgenic mice are sensitive to low doses of streptozotocin-induced type I diabetes mellitus. Acta Pharmacol. Sin. 2004, 24, 1199–1204
[46]	Ajebli, M.; Khan, H.; Eddouks, M. Natural alkaloids and diabetes mellitus: a review. Endocr. Metab. Immune. Disord Drug Targets. 2021, 21, 111–130.
[47]	Feng, J.J.; Zheng, J.G.; Liu, J.L. Pathogenesis of mild cognitive impairment on Chinese medicine and Western medicine: review. J. Changchun Univ. Tradit. Chin. Med. 2014, 30, 1166–1169.
[48]	Huang, K.; Huang, R.; Zuo, X.T.; Ruan, Z.Z. Overview of the treatment of obesity type 2 diabetes with external treatment of traditional Chinese medicine. Tradit. Chin. Med. 2021, 10, 188–192.
[49]	Meng, J.N.; Zhu, Y.F.; Ma, H.X.; Wang, X.B.; Zhao, Q.P. The role of traditional Chinese medicine in the treatment of cognitive dysfunction in type 2 diabetes. J. Ethnopharmacol. 2021, 280, 114464.
[50]	Lin, J.T.; Liu, J.H.; Liu, X.H. Effect of compound Danshen Dropping Pills on cognitive function in diabetic patients with coronary heart disease. China J. New Drugs. 2009, 13, 43–46.
[51]	Yuan, M.X.; He, Q.; Long, Z.Y.; Zhu, X.F.; Xiang, W.; Wu, Y.H.; Lin, S.B. Exploring the pharmacological mechanism of Liuwei Dihuang decoction for diabetic retinopathy: a systematic biological strategy-based research. Evid. Based Complement. Altern. Med. 2021, 2021, 5544518.
[52]	Liu, J.P.; Feng, L.; Zhang, M.H.; Ma, D.Y.; Wang, S.Y.; Gu, J.; Fu, Q.; Qu, R.; Ma, S.P. Neuroprotective effect of Liuwei Dihuang decoction on cognition deficits of diabetic encephalopathy in streptozotocin-induced diabetic rat. J. Ethnopharmacol. 2013, 150, 371–381.
[53]	Wu, J.Z.; Ardah, M.; Haikal, C.; Svanbergsson, A.; Diepenbroek, M.; Vaikath, N.N.; Li, W.; Wang, Z.Y.; Outeiro, T.F.; El-Agnaf, O.M.; Li, J.Y. Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy. Transl. Neurodegener. 2019, 8, 18.
[54]	Ren, Z.X.; Zhao, Y.F.; Cao, T.; Zhen, X.C. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson’s disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol. Sin. 2016, 37, 1315–1324.